Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.

Cancer letters - 1 Jun 2025

Uemoto Yasuaki, Lin Chang-Ching A, Wang Bingnan, Ye Dan, Fang Yisheng V, Bikorimana Emmanuel, Napolitano Fabiana, Chica-Parrado Maria Rosario, Li Cheung, Mendiratta Saurabh, Chen Chuo, Hanker Ariella B, Arteaga Carlos L

Abstract excerpt

FGFR1 amplification and FGFR1/2 activating mutations have been associated with antiestrogen resistance in estrogen receptor-positive (ER+) breast cancer. However, there are no approved FGFR1-targeted therapies for breast cancers harboring these alterations. In this study, we investigated the selective degradation of FGFR1/2 using the proteolysis-targeting chimera (PROTAC) DGY-09-192 as a novel therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Receptors, Estrogen
Share to Estrogen Receptor alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fulvestrant

Share to MCF-7 Cells

Share to Proteolysis

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40127812
DOI: 10.1016/j.canlet.2025.217668
PMCID: PMC12143203

Genes

FGFR1
FGFR2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations.PMID 40127812Read ↗

A Selective FGFR1/2 PROTAC Degrader with Antitumor ActivitySemantic proximity Read ↗

Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer In Vitro and In VivoSemantic proximity Read ↗

Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor.Semantic proximity Read ↗

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.Semantic proximity Read ↗

Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer.Semantic proximity Read ↗

FGFR blockade inhibits targeted therapy-tolerant persister cells in basal FGFR1 and FGF2 high expressing cancers with driver oncogenesSemantic proximity Read ↗

Current Status of Fibroblast Growth Factor Receptors Targeted Therapies in Breast CancerSemantic proximity Read ↗

FGFR rearrangements: oncogenic drivers and therapeutic targets.Semantic proximity Read ↗

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerSemantic proximity Read ↗

FGFR-TKI resistance in cancer: current status and perspectives.Semantic proximity Read ↗

Future applications of FGF/FGFR inhibitors in cancer.Semantic proximity Read ↗

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.